WordNet

of or producing or containing serum; "a serous exudate"

PrepTutorEJDIC

漿液(しょうえき)状の,漿液を含む / 水のような,希薄な

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/09/22 13:31:26」(JST)

wiki en

[Wiki en表示]

In physiology, the term serous fluid or serosal fluid is used for various bodily fluids that are typically pale yellow and transparent, and of a benign nature, that fill the inside of body cavities. Serous fluid originates from serous glands, with secretions enriched with proteins and water. Serous fluid may also originate from mixed glands, which contain both mucous and serous cells. A common trait of serous fluids is their role in assisting digestion, excretion, and respiration.

In medical fields, especially cytopathology, serous fluid is a synonym for effusion fluids from various body cavities. There are many causes of effusions which include involvement of the cavity by cancer. Cytopathology evaluation is recommended to evaluate the causes of effusions in these cavities.^[1]

Examples[edit source | edit]

Saliva consists of mucus and serous fluid; the serous fluid contains the enzyme amylase important for the digestion of carbohydrates. Minor salivary glands of von Ebner present on the tongue secrete the amylase. The parotid gland produces purely serous saliva. The other major salivary glands produce mixed (serous and mucus) saliva.

Another type of serous fluid is secreted by the serous membranes (or serosa), two layered membranes which line the body cavities. The serous fluid between the two layers acts as a lubricant and reduces friction from muscle movement. This can be seen in the lungs. Cytopathologic evaluation is recommended to diagnose the causes of fluid accumulation which include involvement of the cavity by cancer.^[1]

Blood serum is the liquid part of blood remaining after clotting, and is therefore lacking in clotting factors and distinct from blood plasma.

References[edit source | edit]

^ ^a ^b Shidham, Vinod B.; Atkinson, Barbara F. (2007). Cytopathologic diagnosis of serous fluids (1 ed.). Philadelphia, Pennsylvania: Saunders Elsevier. ISBN 978-1-4160-0145-4.

This anatomy article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における急性中耳炎（化膿性および漿液性） acute otitis media in adults suppurative and serous
2. 小児における滲出液を伴う中耳炎（滲出性中耳炎） otitis media with effusion serous otitis media in children
3. 上皮性卵巣癌、卵管癌、または原発性腹膜癌患者の付属器腫瘤の評価のための血清
バイオマーカー serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary fallopian tube or peritoneum
4. 漿液性の卵巣癌、卵管癌、および腹膜癌の病因 pathogenesis of ovarian fallopian tubal and peritoneal serous carcinomas
5. 高リスクの子宮体癌に対する補助化学療法 adjuvant treatment of high risk endometrial cancers

English Journal

Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Saldanha SN, Tollefsbol TO.Author information Department of Biology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Biological Sciences, Alabama State University, Montgomery, Alabama.AbstractCellular pathways are numerous and are highly integrated in function in the control of cellular systems. They collectively regulate cell division, proliferation, survival and apoptosis of cells and mutagenesis of key genes that control these pathways can initiate neoplastic transformations. Understanding these pathways is crucial to future therapeutic and preventive strategies of the disease. Ovarian cancers are of three major types; epithelial, germ-cell, and stromal. However, ovarian cancers of epithelial origin, arising from the mesothelium, are the predominant form. Of the subtypes of ovarian cancer, the high-grade serous tumors are fatal, with low survival rate due to late detection and poor response to treatments. Close examination of preserved ovarian tissues and in vitro studies have provided insights into the mechanistic changes occurring in cells mediated by a few key genes. This review will focus on pathways and key genes of the pathways that are mutated or have aberrant functions in the pathology of ovarian cancer. Non-genetic mechanisms that are gaining prominence in the pathology of ovarian cancer, miRNAs and epigenetics, will also be discussed in the review. J. Cell. Physiol. 229: 393-406, 2014. © 2013 Wiley Periodicals, Inc.
Journal of cellular physiology.J Cell Physiol.2014 Apr;229(4):393-406. doi: 10.1002/jcp.24466.
Cellular pathways are numerous and are highly integrated in function in the control of cellular systems. They collectively regulate cell division, proliferation, survival and apoptosis of cells and mutagenesis of key genes that control these pathways can initiate neoplastic transformations. Understa
PMID 24105793

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.

Park SH1, Song JY2, Kim YK2, Heo JH3, Kang H3, Kim G2, An HJ2, Kim TH2.Author information 1Department of Gynecologic Oncology, CHA Gangnam Medical Center, Gangnam-Gu, Seoul 135-907, Republic of Korea.2Clinical Research Institute, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.3Department of Pathology, CHA Bundang Medical Center, CHA University, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 463-712, Republic of Korea.AbstractFascin1 (FSCN1) involved in cell motility and filopodia assembly plays important roles in biological processes such as cancer invasion and metastasis of multiple epithelial tumors. High-grade serous ovarian carcinoma (HGSOC) is aggressive and metastatic by acquiring an invasive phenotype and this step requires remodeling of the actin cytoskeleton. Thus, the present study aimed to investigate the expression of fascin1 in HGSOC tissues as well as its clinical significance such as prognostic predictors and its utility of therapeutic target. Fascin1 and β-catenin were evaluated using immunohistochemistry on a tissue microarray of 79 HGSOC. Small interfering RNA (siRNA) approach was used to knock down fascin1 expression in ovarian cancer cell lines to determine whether fascin1 contributes to tumor cell proliferation, migration and invasion. Fascin1 expression levels were determined by western blot analysis after siRNA transfection using two human ovarian cancer cell lines (SKOV3 and OVCAR3). Fascin1 overexpression was significantly correlated with lymph node involvement, distance metastasis and high International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV) (P<0.05). A Kaplan-Meier analysis showed that the fascin1 expression group was significantly associated with poor overall survival (P=0.010). We showed that inactivation of fascin1 by siRNA transfection led to a drop in cell viability, and significantly decreased tumor cell proliferation, migration and invasiveness compared to untransfected cells. We found that fascin1 expression is a potential poor marker of prognosis for patients with HGSOC and knockdown of fascin1 suppresses ovarian cancer cell proliferation and migration, this could be applied for therapeutic targets in ovarian cancer treatment.
International journal of oncology.Int J Oncol.2014 Mar;44(3):637-46. doi: 10.3892/ijo.2013.2232. Epub 2013 Dec 30.
Fascin1 (FSCN1) involved in cell motility and filopodia assembly plays important roles in biological processes such as cancer invasion and metastasis of multiple epithelial tumors. High-grade serous ovarian carcinoma (HGSOC) is aggressive and metastatic by acquiring an invasive phenotype and this st
PMID 24378809

Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome.

von Heideman A, Tholander B, Grundmark B, Cajander S, Gerdin E, Holm L, Axelsson A, Rosenberg P, Mahteme H, Daniel E, Larsson R, Nygren P.Author information Department of Radiology, Oncology and Radiation Science, Uppsala University , Uppsala , Sweden.AbstractAbstract Background. A number of chemotherapeutic drugs are active in epithelial ovarian cancer (EOC) but so far choice of drugs for treatment is mostly empirically based. Testing of drug activity in tumour cells from patients might provide a rationale for a more individualised approach for drug selection. Material and methods. Sensitivity of EOC to chemotherapeutic drugs was analysed in 125 tumour samples from 112 patients using a short-term primary culture assay based on the concept of total cell kill. Sensitivity was related to tumour histology, treatment status and clinical tumour response. Results. For most EOC standard drugs serous high grade and clear cell EOC were the most sensitive subtypes and the mucinous tumours the most resistant subtype. Docetaxel, however, tended to show the opposite pattern. Samples from previously treated patients tended to be more resistant than those from treatment naïve patients. The activity of cisplatin correlated with that of other drugs with the exception of docetaxel. Tumour samples from two sites in the same patient at the same occasion showed similar cisplatin sensitivity in contrast to samples taken at different occasions. Samples from patients responding in the clinic to treatment were more sensitive to most drugs than samples from non-responding patients. At the individual patient level, drug sensitivity in vitro compared with clinical response showed sensitivities and specificities in the 83-100% and 55-83% ranges, respectively. Conclusions. Assessment of EOC tumour cell drug sensitivity in vitro provides clinically relevant and potentially useful information for the optimisation of drug treatment.
Acta oncologica (Stockholm, Sweden).Acta Oncol.2014 Feb;53(2):242-50. doi: 10.3109/0284186X.2013.794956. Epub 2013 May 29.
Abstract Background. A number of chemotherapeutic drugs are active in epithelial ovarian cancer (EOC) but so far choice of drugs for treatment is mostly empirically based. Testing of drug activity in tumour cells from patients might provide a rationale for a more individualised approach for drug sel
PMID 23713890

Japanese Journal

当院における純粋型子宮体部漿液性腺癌13例の治療成績

神奈川産科婦人科学会誌 = Kanagawa journal of obstetrics and gynecology : official journal, Kanagawa Society of Obstetrics and Gynecology 52(1), 19-23, 2015-09
NAID 40020623646